Imatinib US FDA Label
- Compound: 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
- Description: Imatinib is a benzamide obtained by formal condensation of the carboxy group of 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid with the primary aromatic amino group of 4-methyl-N(3)-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine. Used (as its mesylate salt) for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours. It has a role as an apoptosis inducer, a tyrosine kinase inhibitor and an antineoplastic agent. It is a N-methylpiperazine, a member of pyridines, a member of benzamides, an aromatic amine and a member of pyrimidines. It is functionally related to a benzamide.
- Brand Name:
- Code(s): STI571
- Approved:
- Kinase Class: NRY
- Inhibitor Type: IIA, I
- Literature (PubMed): 0
- Target(s): ABL proto-oncogene 1, non-receptor tyrosine kinase , KIT proto-oncogene, receptor tyrosine kinase , Platelet derived growth factor receptor alpha , Platelet derived growth factor receptor beta
- Disease(s): acute lymphocytic leukemia , aggressive systemic mastocytosis , chronic eosinophilic leukemia , chronic myeloid leukemia